Background: The treatment of vitiligo is often challenging and requires a multi-modality approach. Fractional carbon dioxide (FCO) laser has been studied as an adjuvant therapy in cases of vitiligo. Autologous platelet-rich plasma (PRP) is rich in growth factors, which may contribute to the growth of melanocytes, and thus help in the repigmentation of vitiligo patches. We aimed to study the combination of these two modalities for the treatment of vitiligo.
Aims And Objective: The aim of this study was to compare the efficacy and safety of FCO laser with PRP and FCO laser alone as an adjuvant therapy in stable non-segmental vitiligo (NSV) patients.
Settings And Design: A prospective, randomized, comparative, open-label interventional study was carried out for a period of 18 months from December 2017 to June 2019, at a tertiary care hospital.
Materials And Methods: Seventy patients with stable, NSV were assessed for eligibility; 66 patients were randomized equally into two groups. Group A received treatment with FCO laser with intralesional PRP, whereas Group B was treated with FCO laser alone. Patients in both the groups were treated with one therapy session and were followed up monthly for a period of 3 months. All the patients received topical psoralen with ultraviolet A (UVA) PUVA-sol treatment. Baseline and monthly assessments were done by VITILIGO AREA SEVERITY INDEX and standardized photographs.
Results: VASI score reduction was significantly more in the Group A with (mean ± standard deviation [SD]) 9.5 ± 0.22, 5.8 ± 1.12, and 3.6 ± 1.81 as compared to Group B 11.9 ± 2.83, 9.9 ± 3.11, and 8.9 ± 3.46 at each subsequent follow-up visits, respectively. Side effects such as burning sensation, erythema, and crusting were seen less frequently and lasted for a short period in Group A in comparison to those in Group B.
Conclusion: Combination of FCO laser and autologous intralesional PRP has a synergetic effect in treating patients with vitiligo as an adjuvant therapy with minimal adverse effects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149972 | PMC |
http://dx.doi.org/10.4103/JCAS.JCAS_188_19 | DOI Listing |
Lasers Surg Med
January 2025
Dermatology, Venereology and Andrology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Background: Alopecia areata (AA) is a chronic inflammatory disease that affects the hair follicles and sometimes the nails. It usually presents as a single or multiple patches of hair loss on the scalp, but any hair-bearing skin can be involved. AA treatment depends on the severity and extent of the disease.
View Article and Find Full Text PDFLasers Med Sci
June 2024
Department of Dermatology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Int J Dent Hyg
November 2024
Dental Science School (Faculdade de Ciências Odontológicas-FCO), Montes Claros, Brazil.
J Cosmet Dermatol
May 2024
Pathology and Stem Cell Research Center, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran.
Background: Transepidermal drug delivery is a novel therapeutic technique to boost efficacy of topical drugs.
Aim: In this clinical trial we evaluate the efficacy of the combination of fractional carbon dioxide (FCO) laser and bimatoprost solution compared to bimatoprost alone in the treatment of alopecia areata.
Methods: This is a prospective intra-patient comparative randomized clinical trial on 20 patients with alopecia areata.
J Cosmet Dermatol
May 2024
Department of Dermatology, The First Hospital of China Medical University, Shenyang, China.
Background: The current nursing procedure after fractional carbon dioxide (fCO) is complex and needs to be optimized. The present study was conducted to evaluate the assisting effect of filament coating system after fCO laser treatment.
Methods: Chinese individuals aged from 18 to 65 years diagnosed as photoaging or atrophic acne scar were recruited and each participant was treated with one single pass of fCO laser.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!